A resident of Medford, NJ, Dr. Adamson received his MD from Cornell University Medical College and performed his pediatric residency at The Children’s Hospital of Philadelphia from 1984 to 1987. He then became a fellow in Pediatric Hematology/Oncology at the National Cancer Institute, where he also served as a Biotechnology fellow, a Children’s Cancer Foundation Research Scholar, an investigator and an attending physician over the course of 12 years before returning to Children’s Hospital of Philadelphia. He was elected by principal investigators of more than 200 Children's Oncology Group sites. COG unites more than 5,000 experts in childhood cancer at leading children’s hospitals, universities and cancer centers across North America, Australia, New Zealand and Europe in the fight against childhood cancer.

Dr. Adamson's broad experience working with many investigators and industry partners, his own extensive research efforts, and his participation in key scientific committees of the National Cancer Institute give him a unique perspective on the challenges facing the cancer clinical trial system. Dr. Adamson’s previous roles at Children's Oncology Group have included leading a 21-site phase 1 consortium that conducted initial evaluations of drugs being developed to treat cancer in children.

In 2020, Dr. Adamson was named global development therapeutic area head of oncology and pediatric innovation at Sanofi, where he is leading the global development in cancer, and working with leaders across therapeutic areas to further pediatric drug development efforts.